Imaging Diagnostic Systems To Collaborate With Florida International University

FORT LAUDERDALE, Fla., July 10 /PRNewswire-FirstCall/ -- Imaging Diagnostic Systems, Inc., announced a collaboration with Florida International University's Department of Biomedical Engineering (BME). Anuradha Godavarty, PhD, Assistant Professor at the BME and the Director of the Optical Imaging Laboratory, will be the lead investigator.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040412/IMDSLOGO )

The Company entered into a collaborative agreement with FIU to support portions of its proprietary CTLM advanced technology development. FIU, known as Miami's public research university, emphasizes research as a major component of its mission. It is ranked as a Research University with High Research Activity in the Carnegie Foundation's classification system.

"We are fortunate to have the opportunity to work with such a respected and experienced researcher who is also part of our local academic community," stated Steven L. Ponder, PhD, IDSI's Director of Advanced Development.

Dr. Godavarty's research focuses on optical-based molecular imaging and tomography. She has investigated medical optical imaging techniques for over seven years.

"Our Optical Imaging Laboratory at FIU is excited to collaborate with IDSI, as our common goal is breast cancer diagnostic imaging using optical tools. Having an industry collaborator is vital toward the translation of the technology from academic research," said Dr. Godavarty.

The Company's CTLM system recently entered US clinical trials to gather data for submission of a PMA application.

Imaging Diagnostic Systems is seeking FDA Premarket Approval (PMA) for its Computed Tomography Laser Mammography (CTLM(R)) system to be used as an adjunct to mammography. The FDA has determined that the Company's clinical investigation is a non-significant risk (NSR) investigational device study because it does not meet the definition of a significant risk (SR) device under 812.3(m) of the investigational device exemptions (IDE) regulation (21 CFR 812). The CTLM(R) system is the first patented breast imaging system that utilizes state-of-the-art laser technology and patented algorithms to create 3-D images of the breast. It is a non-invasive, painless examination that does not expose the patient to radiation or require breast compression. The CTLM system is limited by United States Federal Law to investigational use only in the United States. Imaging Diagnostic Systems has received CE Marking, CMDCAS (Canada), Canadian License, China SFDA approval, UL listing, ISO 9001:2000, ISO 13485:2003 certification and FDA export certification for its CT Laser Mammography system.

Please visit Imaging Diagnostic Systems' website at: http://www.imds.com for additional information.

As contemplated by the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future, anticipated, or projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates or predictions of future results or events and there can be no assurance that actual results or events will not materially differ from expectations. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company's filings with the Securities and Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements.

Investor Relations: Rick Lutz 404-261-1196 lcgroup@mindspring.com

Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20040412/IMDSLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comImaging Diagnostic Systems, Inc.

CONTACT: Rick Lutz, +1-404-261-1196, or lcgroup@mindspring.com, forImaging Diagnostic Systems

Web site: http://www.imds.com/